Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Tempest Therapeutics, Inc. Director's Dealing 2018

Dec 12, 2018

34632_dirs_2018-12-11_c9215fad-9104-475c-a7b2-697432a9a1eb.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Millendo Therapeutics, Inc. (MLND)
CIK: 0001544227
Period of Report: 2018-12-07

Reporting Person: Arcudi III Louis J (Chief Financial Officer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-12-07 Employee Stock Option (right to buy) $10.395 A 74400 Acquired 2028-12-06 Common Stock (74400) Direct

Footnotes

F1: Twenty-five percent (25%) of the shares subject to the option shall vest on November 1, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.